Hamid Moradi

picture of Hamid  Moradi

Associate Director of Nephrology Fellowship Program, Medicine
School of Medicine
Assistant Clinical Professor, Medicine
School of Medicine

M.D., Oregon Health and Sciences University
B.S., University of California, Los Angeles, 1998, Cell, Molecular and Developmental Biology

Phone: (714) 456-5560, 5142, 667
Email: hmoradi@uci.edu

University of California, Irvine
City Tower, Suite 400
Mail Code: 4067
Irvine, CA 92697
Research Interests
High Density Lipoprotein, HDL function, End stage renal disease, Dialysis, Lipid metabolism, Lipid Derived Mediators
Academic Distinctions
-Orange County Medical Association Physician of Excellence 2015
-Member of the Dialysis Advisory Group (DAG) ASN 2015-2018
-Southern California Rising Stars Super Doctors 2014
-Marquis Who's Who® 2014
-Fellow of American Society of Nephrology 2012
-Fellow of American College of Physicians 2013
-Best Abstract annual meeting International Society of Blood Purification 2010
-First place winner – Scientific poster at the NKF-Kaiser Permanente Annual Meeting 2009 (Anaheim)
-Second place winner in basic science research. Young Investigator forum 2009.
-AFMR Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2009
-Carmel Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2008
-Endocrinology Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2006
-Recipient of Alpha Omega Alpha (medical honor society) summer research fellowship OHSU 2000
-B.S. Suma Cum Laude with departmental honors UCLA 1997
Appointments
Staff Physician- Long Beach VA Healthcare System
Principle Investigator- Long Beach VA Healthcare System
Publications
1. Klein, K., Reiter, R., Redula, J., Moradi, H., Zhu, X., Brothman, A., Lamb, D., Marcelli, M., Belldegrun, A., Witte, O., Sawyers, C. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. 1997. Nat Med. Apr; 3: 402-8.

2. Moradi, H., Kwok, V., Vaziri, ND. Effect of chronic renal failure on arginase and argininosuccinate synthetase expression. Am J Nephrol. 2006; 26: 310-8.

3. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009; 153: 77-85.

4. Pahl, M., Ni, Z., Sepassi, L., Moradi, H.,Vaziri ND. Plasma Phospholipid Transfer Protein, Cholesteryl Ester Transfer Protein and Lecithin: Cholesterol Acyltransferase In End-Stage Renal Disease (ESRD). Nephrol Dial Transplant. 2009; 24: 2541-6.

5. Moradi H., Yuan J., Norris K., Vaziri ND. Reverse cholesterol transport pathway in experimental renal failure. Am J Nephrol. 2009 24; 30:147-154.

6. Kim, H.J., Moradi, H., Yuan, J., Vaziri, ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009; 296: F1297-306.

7. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009; 76: 437-44.

8. Moradi, H., Ganji, S., Kamanna, V., Pahl, M.,Vaziri, ND. Antioxidant therapy does not improve inflammation or antioxidant activity in end-stage renal disease. Clin Nephrol. 2010; 74: 273-81.

9. Vaziri ND, Kim HJ, Moradi H, Farmand F, Navab K, Navab M, Hama S, Fogelman AM, Quiroz Y, Rodriguez-Iturbe B.. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrol Dial Transplant. 2010; 25: 3525-34.

10. Vaziri, ND., Moradi, H., Pahl, M., Gollapudi, P., Barton, C.H., Navab, M. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011; 103: 524-33.

11. Bukhari, FJ, Moradi, H., Kim, HJ., Vaziri, ND., Said, HM. Effect of chronic kidney disease on the expression of Thiamin and Folic acid transporters. Nephrol Dial Transplant. 2011; 26: 2137-44.

12. Vaziri ND, Gollapudi P, Han S, Farahmand G, Yuan J, Rahimi A, Moradi H. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor. Nephrol Dial Transplant. 2011; 26: 3118-23.

13. Vaziri, ND, Goshtasbi, N, Yuan, J, Jellbauer, S, Moradi, H, Raffatellu M, Kalantar-Zadeh K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012; 36: 438-43.

14. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res. 2013 ;161:477-85

15. Han, SY, Vaziri, ND, Gollapudi, P, Kwok, V, Moradi, H. Hepatic fatty acid and cholesterol metabolism in nehprotic syndrome. Am J Transl Res. 2013; 5: 246-53. (corresponding author)

16. Subramanian VS, Nabokina SM, Patton JR, Marchant JS, Moradi H, Said HM. Glyoxalate reductase/hydroxypyruvate reductase interacts with the sodium-dependent vitamin C transporter-1 to regulate cellular vitamin C homeostasis. Am J Physiol Gastrointest Liver Physiol. 2013; 304: G1079-86.

17. Lertdumrongluk P, Rhee CM, Park J, Lau WL, Moradi H, Jing J, Molnar MZ, Brunelli SM, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K. Association of Serum Phosphorus Concentration With Mortality in Elderly and Nonelderly Hemodialysis Patients. J Ren Nutr. 2013; 23:411-21.

18. Yazdi PG*, Moradi H*, Yang JY, Wang PH, Vaziri ND. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med. 2013; 6: 532-9. (Co First-Author)

19. Hatamizadeh P, Ravel V, Lukowsky LR, Molnar MZ, Moradi H, Harley K, Pahl M, Kovesdy CP, Kalantar-Zadeh K. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant. 2013; 28: 2889-98.

20. Rhee CM, Lertdumrongluk P, Streja E, Park J, Moradi H, Lau WL, Norris KC, Nissenson AR, Amin AN, Kovesdy CP, Kalantar-Zadeh K. Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities. Am J Nephrol. 2014;39:183-94.

21. Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014;29:1554-62.

22. Li L, Fisher M, Lau WL, Moradi H, Cheung A, Thai G, Handwerker J, Kalantar-Zadeh K. Cerebral microbleeds and cognitive decline in a hemodialysis patient: Case report and review of literature. Hemodial Int. 2015; 19: E1-7.

23. Kalantar-Zadeh K, Tortorici AR, Chen JL, Kamgar M, Lau WL, Moradi H, Rhee CM, Streja E, Kovesdy CP. Dietary Restrictions in Dialysis Patients: Is There Anything Left to Eat? Semin Dial. 2015; 28: 159-68.

24. Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, Gillen D, Pahl MV, Vaziri ND, Kalantar-Zadeh K. Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. Am J Nephrol. 2015; 41: 284-95.

25. Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, Nakata T, Kovesdy CP, Brent GA, Kalantar-Zadeh K. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2015; 66: 313-21.

26. Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H, Molnar MZ, Reddy U, Amin AN, Kovesdy CP, Kalantar-Zadeh K. Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. J Am Med Dir Assoc. 2015; 16: 933-9.

27. Ravel V, Streja E, Molnar MZ, Rezakhani S, Soohoo M, Kovesdy CP, Kalantar-Zadeh K, Moradi H. Association of aspartate aminotransferase with mortality in hemodialysis patients. Nephrol Dial Transplant. 2015 Sep 1. pii: gfv310.

28. Doshi M, Streja E, Rhee CM, Park J, Ravel VA, Soohoo M, Moradi H, Lau WL, Mehrotra R, Kuttykrishnan S, Kovesdy CP, Kalantar-Zadeh K, Chen JL. Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial Transplant. 2015 Nov 19. pii: gfv379.





Editorials

1. Moradi H, Wang P. Renoprotective mechanisms of ischemic postconditioning in ischemia–reperfusion injury: improved mitochondrial function and integrity. Nephrol Dial Transplant. 2013; 28: 2667-9.

2. Dual role of circulating angiopoietin-like 4 (ANGPTL4) in promoting hypertriglyceridemia and lowering proteinuria in nephrotic syndrome.
Vaziri ND, Moradi H. Am J Kidney Dis. 2014 Oct;64(4):495-8.




Reviews

1. Vaziri, ND, Moradi, H. 2006. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. Jan; 10(1):1-7.

2. Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword. J Ren Nutr. 2013; 23: 203-6.

3. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013; 38: 136-48.

4. Streja E, Kovesdy CP, Streja DA, Moradi H, Kalantar-Zadeh K, Kashyap ML.
Niacin and Progression of CKD. 2015; 65: 785-98.
Grants
1 IK CX 001043-01A2 VA ORD Career Development Award
2009-2013 NIH F32-DK-082130 NRSA Post-Doctoral Fellowship 2007-2008
Professional Society
American Society of Nephrology
Last updated
07/05/2018